Peter Slavin M.D.

Peter Slavin, MD, serves as the President and CEO Elect at Cedars-Sinai as of July 2024 and holds the position of Operating Partner at Advent International since April 2022. Slavin has been a Board Member at Amwell and Point32Health since December 2016 and September 2022, respectively. Additionally, Slavin provides advisory services to Tredence Inc., Droplet Biosciences, Inc., Joyous, Florence, and Perry Health, all since early 2023. An Advisory Board Member at Arsenal Capital Partners since June 2015, Slavin possesses a strong educational background, including a Doctor of Medicine degree from Harvard Medical School and an MBA from Harvard Business School, along with a Bachelor of Arts in Biochemical Sciences from Harvard University.